BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12810463)

  • 21. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
    Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
    Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p12CDK2-AP1 gene therapy strategy inhibits tumor growth in an in vivo mouse model of head and neck cancer.
    Figueiredo ML; Kim Y; St John MA; Wong DT
    Clin Cancer Res; 2005 May; 11(10):3939-48. PubMed ID: 15897596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
    Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
    Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of hepatocellular carcinoma by transfecting interleukin-12 and interleukin-2 fusion gene intrasplenically, an experimental study].
    Yang JH; Fan RF; Qian QJ; You TG; Xue HB; Su CQ; Cao HF; Wu MC
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):740-3. PubMed ID: 12899748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
    Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
    Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
    Zhang SW; Xiao SW; Liu CQ; Sun Y; Su X; Li DM; Xu G; Zhu GY; Xu B
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):426-8. PubMed ID: 16188130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alloantigen gene therapy for head and neck cancer: evaluation of animal models.
    Gleich LL; Li YQ; Li S; Gluckman JL; Stambrook PJ
    Head Neck; 2003 Apr; 25(4):274-9. PubMed ID: 12658731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FasL gene therapy: a new therapeutic modality for head and neck cancer.
    ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
    Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of murine Lewis lung cancer with recombinant interleukin-12].
    Yin XL; Duan H; Peng ZP; Sun SL; Li SL
    Ai Zheng; 2006 Sep; 25(9):1087-91. PubMed ID: 16965647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery.
    Pan PY; Li Y; Li Q; Gu P; Martinet O; Thung S; Chen SH
    Cancer Immunol Immunother; 2004 Jan; 53(1):17-25. PubMed ID: 12955480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
    Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma.
    Khan MK; Mamou F; Schipper MJ; May KS; Kwitny A; Warnat A; Bolton B; Nair BM; Kariapper MS; Miller M; Brewer G; Normolle D; Merajver SD; Teknos TN
    Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):333-8. PubMed ID: 16549755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
    Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
    Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of suicide gene therapy in combination with immunotherapy on antitumour immune response & tumour regression in a xenograft mouse model for head & neck squamous cell carcinoma.
    Ambade AV; Joshi GV; Mulherkar R
    Indian J Med Res; 2010 Oct; 132():415-22. PubMed ID: 20966520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antitumour study with combined IL-2 gene therapy and radiation for head and neck squamous cell carcinoma].
    Liu S; Yang H; Tang Z; Liang C
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 17(2):105-7. PubMed ID: 12833697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adoptive T cell transfer augments IL-2 mediated tumour regression in a HNSCC xenograft nude mouse model.
    Ambade A; Mulherkar R
    Cancer Lett; 2008 Dec; 272(2):316-24. PubMed ID: 18762367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y; Zou YY; Xia WY; Hung MC
    Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.